Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

D-Pharm Selects Tigermed for Trial of Stroke Drug

publication date: Nov 4, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
D-Pharm of Israel will entrust Hangzhou Tigermed Consulting Co. with a Phase III China clinical trial of its stroke treatment. Tigermed will also be in charge of China regulatory filings for DP-b99, a neuroprotective drug. Wanbang Biopharma, which will market the drug in China for D-Pharm, also signed the contract. More details....

Stock Symbol: (TASE: DPRM)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors